Therapeutic Areas of 327 Products in the VBP List
The 327 products are classified into 60 categories based on the types and content ratios of active ingredients in finished dosage forms. Among the 60 categories,
- 12 categories are anti-infection medicines, such as Ornidazole Tablets, Clindamycin Phosphate Injection, and Roxithromycin Tablets;
- 3 categories are for hypertension;
- 3 for diabetes;
- 2 for non-small cell lung cancer.
Benefits and Limits of VBP
Basically, VBP is a program carried out by Chinese governments to make drugs affordable to more patients. For pharmaceutical companies, VBP is a remarkable channel to sell drugs in bulk volumes. But due to lower unit prices, the profit from each sold product decreases. Among the 60 bid-winning drugs in the 7th VBP, 56 are generics while only 4 are originators. This is mainly because generics have larger space for price reduction than innovator drugs, whose companies mostly tend to not slash prices due to their high R&D costs.
How to Bid for VBP in China
Firstly, China's National Joint Drug Procurement Office will announce the requirements for drug to apply for joining the VBP. Usually, the qualified drugs are limited to
- Originator drugs or reference listed drugs;
- Generic drugs that have passed the quality and therapeutic equivalence evaluation;
- In the marketing authorization applications, generic drugs that have proven they are equivalent with the originator drugs/reference listed drugs in quality and efficacy.
- Commitment letter on VBP application;
- Letter of authorization from the legal person;
- The application information form (sealed in an independent package);
- Document proving that the drug is qualified for the VBP application;
- The company's qualification documents (only one set of documents is required if the company has multiple drugs applying for joining in the VBP)
- Document specifying that the active pharmaceutical ingredient (API) is produced by the finished dosage form manufacturer itself (a copy of the drug registration certificate is required when the API manufacturer and the finished dosage form manufacturer share the same legal person);
- Commitment letter on production capacity.
Reference Links
- China National Joint Drug Procure Office Announces the Final Tender Result of the 7th Volume-based Procurement
- 327 Drug Products to Enter China’s 7th Round of Volume-based Procurement (VBP)
- China Kicks off the 7th Round of Volume-based Procurement (VBP) of Drugs
- 6th VBP: China's Insulin VBP Saw Average Price Cut of 48.75%
- 5th VBP: A Record Number of Foreign Companies Win Bidding for China's 5th VBP of Drugs
- 4th VBP: Chinese Market Becomes More Intense for Antidiabetic Drugs
Contact Us
BaiPharm, a subsidiary of REACH24H Consulting Group, is specialized in pharmaceutical industry consultancy services. With our experts across China, Japan, South Korea, the United States, and Europe, BaiPharm is fully qualified to engage in complex market entry projects of finished drugs, APIs, excipients, and packaging materials for most key markets. If you have any questions about pharmaceutical regulatory compliance in China, please feel free to contact us. Tel: +86 (0)571-87007555 Email: customer@reach24h.com
